Avestar Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $838K | Sell |
34,785
-4,023
| -10% | -$105K | 0.05% | 274 |
|
|
2026
Q1 | $1.09M | Buy |
38,808
+2,409
| +7% | +$64.1K | 0.07% | 206 |
|
|
2025
Q4 | $906K | Buy |
36,399
+343
| +1% | +$8.65K | 0.06% | 240 |
|
|
2025
Q3 | $919K | Sell |
36,056
-4,985
| -12% | -$123K | 0.06% | 233 |
|
|
2025
Q2 | $995K | Buy |
41,041
+13,935
| +51% | +$325K | 0.07% | 213 |
|
|
2025
Q1 | $687K | Sell |
27,106
-638
| -2% | -$16.7K | 0.06% | 248 |
|
|
2024
Q4 | $736K | Sell |
27,744
-9,822
| -26% | -$266K | 0.06% | 223 |
|
|
2024
Q3 | $1.09M | Buy |
37,566
+2,103
| +6% | +$61.3K | 0.11% | 142 |
|
|
2024
Q2 | $992K | Buy |
35,463
+9,197
| +35% | +$253K | 0.1% | 152 |
|
|
2024
Q1 | $729K | Buy |
26,266
+5,883
| +29% | +$163K | 0.08% | 184 |
|
|
2023
Q4 | $587K | Buy |
20,383
+3,223
| +19% | +$97.4K | 0.07% | 179 |
|
|
2023
Q3 | $569K | Buy |
17,160
+606
| +4% | +$21.4K | 0.08% | 154 |
|
|
2023
Q2 | $607K | Sell |
16,554
-1,238
| -7% | -$48.2K | 0.1% | 128 |
|
|
2023
Q1 | $726K | Sell |
17,792
-2,450
| -12% | -$106K | 0.13% | 99 |
|
|
2022
Q4 | $1.04M | Buy |
20,242
+3,581
| +21% | +$172K | 0.19% | 72 |
|
|
2022
Q3 | $729K | Sell |
16,661
-3,515
| -17% | -$171K | 0.19% | 83 |
|
|
2022
Q2 | $1.06M | Buy |
20,176
+3,331
| +20% | +$170K | 0.26% | 64 |
|
|
2022
Q1 | $872K | Buy |
16,845
+3,241
| +24% | +$168K | 0.14% | 142 |
|
|
2021
Q4 | $803K | Sell |
13,604
-670
| -5% | -$33.2K | 0.1% | 188 |
|
|
2021
Q3 | $614K | Sell |
14,274
-88
| -0.6% | -$3.9K | 0.08% | 257 |
|
|
2021
Q2 | $562K | Sell |
14,362
-3,498
| -20% | -$136K | 0.08% | 255 |
|
|
2021
Q1 | $693K | Buy |
17,860
+1,748
| +11% | +$62.1K | 0.15% | 140 |
|
|
2020
Q4 | $593K | Buy |
16,112
+5,823
| +57% | +$214K | 0.16% | 115 |
|
|
2020
Q3 | $370K | Buy |
10,289
+93
| +0.9% | +$3.26K | 0.12% | 140 |
|
|
2020
Q2 | $316K | Buy |
10,196
+2,587
| +34% | +$87.9K | 0.14% | 132 |
|
|
2020
Q1 | $236K | Sell |
7,609
-2,345
| -24% | -$79.9K | 0.13% | 139 |
|
|
2019
Q4 | $370K | Buy |
9,954
+1,006
| +11% | +$35.8K | 0.21% | 102 |
|
|
2019
Q3 | $305K | Buy |
8,948
+3,505
| +64% | +$127K | 0.19% | 101 |
|
|
2019
Q2 | $215K | Buy |
5,443
+110
| +2% | +$4.37K | 0.14% | 101 |
|
|
2019
Q1 | $207K | Sell |
5,333
-34
| -0.6% | -$1.36K | 0.14% | 102 |
|
|
2018
Q4 | $214K | Buy |
5,367
+101
| +2% | +$4.19K | 0.15% | 96 |
|
|
2018
Q3 | $211K | Sell |
5,266
-2,025
| -28% | -$78K | 0.12% | 112 |
|
|
2018
Q2 | $242K | Buy |
7,291
+299
| +4% | +$10.2K | 0.15% | 93 |
|
|
2018
Q1 | $225K | Sell |
6,992
-40
| -0.6% | -$1.38K | 0.15% | 83 |
|
|
2017
Q4 | $236K | Buy |
+7,032
| New | +$240K | 0.18% | 70 |
|
Other funds holding PFE
AIM
SLAM
CWP
Avestar Capital's PFE Position: Q2 2026 in Review
Avestar Capital reduced its Pfizer (PFE) stake by 10% in Q2 2026, selling an estimated $105K and leaving 34,785 shares worth $838K. The position accounts for 0.05% of the portfolio, ranked #274.
Avestar Capital first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.09M in Q1 2026. 1,336 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Avestar Capital held 34,785 shares of Pfizer worth $838K as of Q2 2026.
- Avestar Capital sold 4,023 Pfizer shares in Q2 2026, an estimated $105K.
- Pfizer made up 0.05% of Avestar Capital's portfolio in Q2 2026, its #274 holding.
- Avestar Capital first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Avestar Capital's Pfizer position peaked at $1.09M in Q1 2026.
- 1,336 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.